<DOC>
	<DOC>NCT01673282</DOC>
	<brief_summary>This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment regimen.</brief_summary>
	<brief_title>Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>The patient has not received Vimpat® more than 7 days prior to start of NonInterventional Study (NIS) The patient must have a diagnosis of epilepsy with partialonset seizures with or without secondary generalization Based on the physician's clinical judgment, it is in the patient's best interest to be prescribed adjunctive Vimpat® (ie, the decision to prescribe Vimpat® is made by the physician) Patient must be at least 18 years of age The patient must have had at least one seizure within the last 3 months prior to enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Focal Epilepsy</keyword>
	<keyword>Drug Load</keyword>
	<keyword>AED</keyword>
	<keyword>SP1065</keyword>
</DOC>